ALS is almost always fatal. Motor neurons also control the respiratory system. So when they begin to deteriorate and eventually die off, this brings on respiratory complications which impair a person’s ability to breathe. Many ALS patients eventually die from pneumonia.
Posts belonging to Category Uncategorized
The RASCALS Foundation is doing everything it can year-round to spread the message about Lou Gehrig’s disease. In reality, this is everybody’s disease—and there is so much more to do. In addition to raising awareness, we need to raise much-needed financial resources for the ALS community.
Q Therapeutics is moving forward to clinical studies using their proprietary, patented Q-Cells® as a potential therapy for Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig’s disease).
The RASCALS Foundation is pleased to announce that it is once again offering the 2014 Higher Education Scholarship Program to assist families affected by ALS. We would like to acknowledge and thank our newest partner Helping Hands for ALS, a student group associated with John Burroughs High School for their generous participation in making these [...]
AB Science SA, a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces, following the press release from November 4, that the acceleration of the clinical development program in ALS is in line with proof of efficacy experiments conducted in two different models that generated positive results of increased survival.
Please join the Robert A. Stehlin Campaign for ALS (RASCALS) to “Fight ALS One Step At A Time”
on Saturday, Nov. 2nd, Tower Grove Park.
“We’re trying to prime the pump and fund (researchers) before they go into clinical trials,” said Melissa Forsythe, director of the Pentagon’s ALS Research Program. “Our goal every year is to make the very best investment we can.”
Researchers at Houston Methodist Neurological Institute and elsewhere will soon begin phase IIa clinical trials of TDI-132, a drug that in animal models has shown promise in reducing the inflammation associated with Amyotrophic Lateral Sclerosis, also known as ALS or Lou Gehrig’s Disease.
The Robert A. Stehlin Campaign for ALS (R.A.S.C.A.L.S.) is pleased to announce the election of Michael R. Brand to the foundation’s Board of Directors as Secretary, his duties include ensuring that board business is conducted in compliance with its bylaws, providing fiscal oversight, and maintaining a continuity of policies and practices in keeping with 501(c)(3) legal requirements.
Cytokinetics Inc. Announces Initiation of First-Time-in-Humans, Phase I Clinical Trial of CK-2127107
Cytokinetics, Incorporated announced today the initiation of a first-time-in-humans, Phase I clinical trial of CK-2127107 in healthy male volunteers. Cytokinetics is developing CK-2127107, a novel small molecule activator of the fast skeletal muscle troponin complex, for the potential improvement of skeletal muscle function in diseases and medical conditions associated with neuromuscular dysfunction, muscular weakness, and/or muscle fatigue. Like tirasemtiv, the lead drug candidate from the company’s skeletal muscle activator program, CK-2127107 slows the rate of calcium release from the regulatory troponin complex of fast skeletal muscle fibers, which sensitizes the sarcomere to calcium.